Table 3

Summary of response at month 12 with subgroup analysis according to type of disease and MSFC subcategories (mITT population, LOCF method)
Placebo Masitinib
All (n = 6) All (n = 24) PPMS (n = 9) SPMS (n = 15)
Relative change in MSFC score* Mean ± SD -60% ± 190 103% ± 189 134% ± 268 84% ± 130
Relative change in T25FW Mean ± SD 26% ± 55 5% ± 26 13% ± 17 -1% ± 29
Relative change in 9-HPT Mean ± SD 0% ± 13 -7% ± 9 -5% ± 7 -8% ± 10
Relative change in PASAT-3” Mean ± SD 24% ± 30 41% ± 111 19% ± 66 55% ± 131
Absolute change in EDSS score Mean ± SD 0.3 ± 1.0 0.0 ± 0.5 0.1 ± 0.4 0.0 ± 0.5

* Change from to baseline. In the primary endpoint of MSFC an increase represents an improvement in MS-related impairment. mITT = modified intent to treat. LOCF = last observation carried forward. MSFC = multiple sclerosis functional composite score. T25FW = timed 25-foot walk test. 9-HPT = nine ­hole peg test. PASAT-3” = Paced Auditory Serial Addition Test 3 seconds. EDSS = expanded disability status scale.

Vermersch et al.

Vermersch et al. BMC Neurology 2012 12:36   doi:10.1186/1471-2377-12-36

Open Data